How are IQV strangle max profit and max loss calculated?

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the IQV strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 38.90%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$840.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.

What is the breakeven for a IQV strangle?

The breakeven for the IQV strangle priced on this page is roughly $151.60 and $188.40 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current IQV market-implied 1-standard-deviation expected move is approximately 11.15%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.

How does current IQV implied volatility affect this strangle?

IQV ATM IV is at 38.90% with IV rank near 39.20%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.

IQV Strangle Strategy

IQV (IQVIA Holdings Inc.), in the Healthcare sector, (Medical - Diagnostics & Research industry), listed on NYSE.

IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services.

IQV (IQVIA Holdings Inc.) trades in the Healthcare sector, specifically Medical - Diagnostics & Research, with a market capitalization of approximately $28.77B, a trailing P/E of 20.96, a beta of 1.18 versus the broader market, a 52-week range of 134.65-247.05, average daily share volume of 1.8M, a public-listing history dating back to 2013, approximately 89K full-time employees. These structural characteristics shape how IQV stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 1.18 places IQV roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.

What is a strangle on IQV?

A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.

Current IQV snapshot

As of May 15, 2026, spot at $170.66, ATM IV 38.90%, IV rank 39.20%, expected move 11.15%. The strangle on IQV below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.

Why this strangle structure on IQV specifically: IQV IV at 38.90% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 11.15% (roughly $19.03 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated IQV expiries trade a higher absolute premium for lower per-day decay. Position sizing on IQV should anchor to the underlying notional of $170.66 per share and to the trader's directional view on IQV stock.

IQV strangle setup

The IQV strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With IQV near $170.66, the first option leg uses a $180.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed IQV chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 IQV shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$180.00	$4.80
Buy 1	Put	$160.00	$3.60

IQV strangle risk and reward

Net Premium / Debit: -$840.00
Max Profit (per contract): Unbounded
Max Loss (per contract): -$840.00
Breakeven(s): $151.60, $188.40
Risk / Reward Ratio: Unbounded

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.

IQV strangle payoff curve

Modeled P&L at expiration across a range of underlying prices for the strangle on IQV. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

Underlying Price	% From Spot	P&L at Expiration
$0.01	-100.0%	+$15,159.00
$37.74	-77.9%	+$11,385.72
$75.48	-55.8%	+$7,612.45
$113.21	-33.7%	+$3,839.17
$150.94	-11.6%	+$65.89
$188.67	+10.6%	+$27.38
$226.41	+32.7%	+$3,800.66
$264.14	+54.8%	+$7,573.93
$301.87	+76.9%	+$11,347.21
$339.60	+99.0%	+$15,120.49

When traders use strangle on IQV

Strangles on IQV are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the IQV chain.

IQV thesis for this strangle

The market-implied 1-standard-deviation range for IQV extends from approximately $151.63 on the downside to $189.69 on the upside. A IQV long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current IQV IV rank near 39.20% is mid-range against its 1-year distribution, so the IV signal is neutral; the strangle thesis on IQV should anchor more to the directional view and the expected-move geometry. As a Healthcare name, IQV options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to IQV-specific events.

IQV strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. IQV positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move IQV alongside the broader basket even when IQV-specific fundamentals are unchanged. Always rebuild the position from current IQV chain quotes before placing a trade.

Frequently asked questions

What is a strangle on IQV?: A strangle on IQV is the strangle strategy applied to IQV (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With IQV stock trading near $170.66, the strikes shown on this page are snapped to the nearest listed IQV chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are IQV strangle max profit and max loss calculated?: Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the IQV strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 38.90%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$840.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a IQV strangle?: The breakeven for the IQV strangle priced on this page is roughly $151.60 and $188.40 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current IQV market-implied 1-standard-deviation expected move is approximately 11.15%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a strangle on IQV?: Strangles on IQV are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the IQV chain.
How does current IQV implied volatility affect this strangle?: IQV ATM IV is at 38.90% with IV rank near 39.20%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.